van Teunenbroek A, de Muinck Keizer-Schrama S M, Aanstoot H J, Stijnen T, Hoogerbrugge N, Drop S L
Department of Pediatrics, Erasmus University and University Hospital/Sophia Children's Hospital, Rotterdam, The Netherlands.
Metabolism. 1999 Jan;48(1):7-14. doi: 10.1016/s0026-0495(99)90003-3.
To analyze the effects of supraphysiological dosages of growth hormone (GH) on carbohydrate (CH) and lipid metabolism, we investigated 87 girls with Turner syndrome (TS) in two studies: (1) a 4-year GH dose-response (DR) study comparing three groups with stepwise GH dosage increases up to 8 IU/m2/d in girls aged 2 to 11 years, and (2) a 2-year GH administration frequency-response (FR) study in girls aged 11 to 17 years, comparing once-daily (OD) and twice-daily (BID) injections of a total GH dose of 6 IU/m2/d in combination with low-dose ethinyl estradiol (50 ng/kg/d orally). At baseline, impaired glucose tolerance (IGT) was present in 6% of the girls, and at the end of the studies, in 5%. In the DR study, the area under the curve for time-concentration (AUCab) for glucose after an oral glucose tolerance test (OGTT) showed no change over time and no significant difference between any of the study groups. However, in all three DR groups, the AUCab for insulin, fasting glucose, the insulinogenic index, hemoglobin A1c (HbA1c), and urinary C-peptide (uCp) were all significantly higher after 4 years compared with pretreatment (P<.05). In the FR study, group differences were not observed. Compared with healthy Dutch control subjects, the median baseline levels in relatively young girls in the DR study were similar for total cholesterol (TC) and lower for high-density lipoprotein (HDL) cholesterol. In contrast, the median TC levels of relatively older girls in the FR study were higher and HDL levels were similar. With increasing GH dosage in the DR study, median TC and low-density lipoprotein (LDL) levels decreased, whereas median HDL levels increased. The changes after 4 years were significant, including a decrease in the atherogenic index. GH treatment at the supraphysiological dosages used in this study did not increase the frequency of IGT or clinical diabetes. However, we observed an increased insulinogenic index indicative of insulin resistance. Therefore, long-term follow-up study is warranted in these otherwise healthy subjects. OD injection regimens changed the lipid profile toward a more cardioprotective direction with a significant reduction of the TC/HDL cholesterol ratio.
为分析超生理剂量生长激素(GH)对碳水化合物(CH)和脂质代谢的影响,我们在两项研究中对87名特纳综合征(TS)女孩进行了调查:(1)一项为期4年的GH剂量反应(DR)研究,比较了2至11岁女孩中三组逐步增加GH剂量直至8 IU/m²/d的情况;(2)一项为期2年的GH给药频率反应(FR)研究,对象为11至17岁女孩,比较每日一次(OD)和每日两次(BID)注射总量为6 IU/m²/d的GH并联合低剂量炔雌醇(口服50 ng/kg/d)的情况。基线时,6%的女孩存在糖耐量受损(IGT),研究结束时为5%。在DR研究中,口服葡萄糖耐量试验(OGTT)后葡萄糖的时间-浓度曲线下面积(AUCab)随时间无变化,且各研究组之间无显著差异。然而,在所有三个DR组中,4年后胰岛素、空腹血糖、胰岛素生成指数、糖化血红蛋白(HbA1c)和尿C肽(uCp)的AUCab均显著高于治疗前(P<0.05)。在FR研究中,未观察到组间差异。与健康的荷兰对照受试者相比,DR研究中相对年轻女孩的总胆固醇(TC)基线中位数水平相似,高密度脂蛋白(HDL)胆固醇水平较低。相比之下,FR研究中相对年长女孩的TC中位数水平较高,HDL水平相似。在DR研究中,随着GH剂量增加,TC和低密度脂蛋白(LDL)中位数水平降低,而HDL中位数水平升高。4年后的变化显著,包括致动脉粥样硬化指数降低。本研究中使用的超生理剂量GH治疗并未增加IGT或临床糖尿病的发生率。然而,我们观察到胰岛素生成指数增加,提示胰岛素抵抗。因此,对这些原本健康的受试者进行长期随访研究是必要的。OD注射方案使脂质谱向更具心脏保护作用的方向改变,TC/HDL胆固醇比值显著降低。